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Flecainide acetate [ 2,5-di- (2,2,2-trifluoroethoxy ) -N- (2-piperidylmethyl) - 
benzamide acetate; Tambocor@ ] has been shown to markedly suppress ventric- 
ular and supraventricular rhythm disorders [l-7]. Effective serum levels of fle- 
cainide range from ca. 0.2 to 1.0 pg/ml [1,3,6-g]. Although the antiarrhythmic 
efficacy of flecainide acetate is not correlated directly with its serum level, the 
determination of the drug is recommended where drug therapy is ineffective in 
order to differentiate failure of therapy from suboptimal dosing, where adverse 
effects occur, or in order to check a patient’s compliance. 
The aim of this study was to develop a high-performance liquid chromato- 
graphic (HPLC) assay for flecainide acetate which is rapid and accurate in the 
therapeutic range and inexpensive, allowing easy drug monitoring in clinical 
practice. 
EXPERIMENTAL 
Chemicals and reagents 
Flecainide acetate was provided by Kettelhack Riker Pharma (Borken, F.R.G. ) 
and the internal standardp-chlorodisopyramide [ 4-diisopropylamino-2- (4-chlo- 
rophenyl) -2- (2-pyridyl)butyramide] by Albert Roussel Pharma (Wiesbaden, 
0378-4347/88/$03.50 0 1988 Elsevier Science Publishers B.V. 
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F.R.G.); acetonitrile, hydrochloric acid, triethylamine, dichloromethane and so- 
dium hydroxide were obtained from Merck (Darmstadt, F.R.G.); l-octanesul- 
phonic acid (PIC B-8 reagent) came from Waters Assoc. (Eschborn, F.R.G. ) . 
Instruments 
The system consisted of a Model 721 system controller, a 510 HPLC pump, a 
Wisp 710B injector block and a Lambda-Max Model 481 variable-wavelength 
detector, all from Waters Assoc. The absorbance spectrum of flecainide acetate 
(dissolved in 0.01 M hydrochloric acid) was established using a DU 50 spectro- 
photometer (Beckman, Munich, F.R.G. ). 
Chromatographic conditions 
The analysis was performed using a Shandon ODS reversed-phase column (125 
mm x 4.6 mm I.D., particle size 5 pm) (Grom, Ammerbuch, F.R.G. ). The mobile 
phase consisted of 55% A (994 ml water, 5 ml PIC B-8 reagent, 1 ml triethyl- 
amine) and 45% B (acetonitrile). The flow-rate was 1.0 ml/min. The column 
effluent was monitored at 222 nm, using a detector range of 0.02 a.u.f.s. and a 
chart speed of 0.5 cm/min. The injection volume was 200 ~1. 
Standards 
Two stock standard solutions were prepared, containing 10 lug/ml flecainide 
acetate and internal standard in 0.01 M hydrochloric acid, respectively. The so- 
lutions were stable for at least two months if stored at 4°C. A standard working 
solution was obtained by combining aliquots of the stock solutions and diluting 
with hydrochloric acid to concentrations of 1.0 pug/ml for either flecainide acetate 
or the internal standard. 
Sample collections 
Serum was obtained by centrifugation at 900 g for 10 min. Twenty-two serum 
samples from normal volunteers (twelve male, ten female ) were pooled (normal 
pool). Twenty-four serum samples from patients (sixteen male, eight female) 
treated with cardiovascular drugs, such as acebutolol, atenolol, betaxolol, meto- 
prolol, pindolol, sotalol, digoxin, nifedipine, verapamil, amiodarone, mexiletin, 
propafenone, quinidine, phenprocoumon, acenocoumarol, acetylsalicylic acid, di- 
pyridamol, sulfinpyrazone, spironolactone, furosemide, hydrochlorothiazide and 
triamterene, were pooled in four pools (patient pools). Twenty-six serum sam- 
ples from twenty-three patients (sixteen male, seven female) treated with fle- 
cainide (150-400 mg/day ) were analysed individually. 
Extraction procedure 
A 2.0-ml volume of dichloromethane, 1.0 ml of serum, 100 ~1 of 1 M sodium 
hydroxide and 100 ~1 of the stock solution of the internal standard were intro- 
duced into a glass centrifuge tube (Khtner, Tubingen, F.R.G.). The tube was 
closed with a stopper (from Sarstedt, Ntirmbrecht, F.R.G.), vortexed for 60 s and 
centrifuged at 3600 g for 10 min. Subsequently the serum phase was discarded. 
Then 1.0 ml of the dichloromethane phase was transferred to a clean glass tube 
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and evaporated to dryness at room temperature under a stream of nitrogen. The 
residue was redissolved in 500 ~1 of 0.01 M hydrochloric acid. 
Linearity test 
The linearity of the chromatographic procedure was tested for flecainide ace- 
tate and the internal standard by analysing five standard solutions with the con- 
centrations 1.0, 0.75, 0.5, 0.25 and 0.1 pg/ml for each of the components. The 
linearity test of the entire procedure was done with the same standard solutions. 
The amount of each standard required to reach concentrations in the range 0.1-1.0 
pug/ml was introduced into a glass centrifuge tube, and 1.0 ml of the normal pool 
serum was added. Subsequently the spiked serum samples were extracted and 
subjected to the chromatographic analysis. 
Recovery rates 
The recovery rates were determined by comparing the peak areas of flecainide 
acetate and internal standard obtained by analysing a spiked serum sample (100 
~1 of each stock solution standard plus 1.0 ml of the normal pool) with the peak 
areas obtained by direct injection of the standard working solution (1.0 pg/ml 
flecainide acetate and internal standard). 
Quantification 
The determination of the concentration of flecainide in the serum was based 
on calibration graphs obtained from standard solutions (0.1, 0.25, 0.5, 0.75, 1.0 
pg/ml). The lo wer limit of quantification was 0.05 pug/ml. Since the calibration 
graph was linear and the calibration was stable for three months, the calculation 
was performed with the 1.0 pug/ml standard only, using the following formula: 
concentration of flecainide (,ug/ml) 
peak area of flecainide 100 
= peak area of standard 
X 
recovery rate of internal standard 
Method of Boutagy 
In addition to our procedure we tried to use the one of Boutagy et al. [19] 
exactly as described and also using several modifications in order to determine 
plasma flecainide levels. We tried the following modifications: (I) the diethyl 
ether extract was evaporated to dryness under nitrogen and the residue was re- 
dissolved in 0.01 M hydrochloric acid (no use of 0.1 M phosphoric acid) and 
injected; (II) during the last extraction step only 1.5 ml of diethyl ether were 
removed and after evaporating the remaining diethyl ether under nitrogen an 
aliquot of the aqueous phase (0.1 M phosphoric acid) was injected; (III) after 
freezing of the aqueous phase (2 M sodium hydroxide) the diethyl ether was 
removed, evaporated to dryness and then redissolved in 0.01 M hydrochloric acid 
(no use of 0.1 M phosphoric acid} and injected; (IV) after freezing of the aqueous 
phase (2 M sodium hydroxide) the diethyl ether was added to 0.1 M phosphoric 
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acid and (after vortexing and centrifugation ) again the aqueous phase was frozen 
and injected after discarding of the diethyl ether. 
RESULTS 
The linearity test showed, for the entire range tested, a linear relationship be- 
tween concentration and peak area for the standards as well as for the entire 
procedure. The recovery rates (mean -t SD.) were 99.5 + 2.3% for flecainide and 
102.7 A 3.4% for the internal standard (meant- S.D. of ten determinations; the 
TABLE I 
SERUM LEVELS OF FLECAINIDE ACETATE FROM PATIENTS TREATED CHRONI- 
CALLY WITH FLECAINIDE 
Patient No. Oral dose of 
flecainide acetate 
per day 
(mg) 
Serum level of flecainide Serum level per body 
acetate (fig/ml) surface @g/ml m-‘) 
Trough After 3 h Trough After 3 h 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Mean + S.D. 
18 
19 
20 
21 
22 
23 
24 
25 
Mean + SD. 
26 
150 0.49 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
200 
300 
300 
300 
300 
300 
300 
300 
300 
400 
0.48 0.72 0.21 0.32 
0.16 0.48 0.08 0.23 
0.23 0.35 0.13 0.19 
0.09 0.17 0.05 0.09 
0.56 0.62 0.25 0.27 
0.57 0.61 0.29 0.31 
0.78 0.92 0.45 0.54 
0.59 0.89 0.32 0.49 
0.20 0.40 0.10 0.20 
0.54 0.75 0.33 0.45 
0.13 0.34 0.07 0.19 
0.35 0.50 0.16 0.24 
0.25 0.38 0.12 0.19 
0.39 0.54 0.24 0.34 
0.34 0.49 0.18 0.27 
0.27 0.31 0.15 0.17 
0.37I!Io.20 0.5oI!zo.21 0.20f0.11 0.28IkO.12 
0.14 0.68 0.20 0.32 
0.23 0.35 0.12 0.19 
1.00 1.19 0.54 0.65 
0.63 0.88 0.30 0.41 
0.39 0.53 0.26 0.35 
0.32 0.46 0.17 0.25 
0.48 0.64 0.27 0.36 
0.54 0.69 0.29 0.38 
0.5OTO.24 0.68kO.26 0.27kO.13 0.36kO.14 
0.33 
0.57 0.27 0.31 
0.61 0.18 0.33 
Fig. 1. Chromatograms of a hlank from the normal pool (A), of a standard working solution (B) and 
of the serum of a patient receiving flecainide (C). 
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REFERENCE METHOD 
(Keitelhack Riker Phormo Gmbh) 
Fig. 2. Comparison of serum concentrations of flecainide acetate determined both with the present 
HPLC method and the method of Becker [9]. 
technical error of the apparatus was less than 1% for flecainide and the internal 
standard). 
We did not observe any cardiovascular substances as interfering peaks in the 
patients’ pools. The individual levels of flecainide (trough level and 3 h after drug 
intake) are shown in Table I. A typical chromatogram obtained from the analysis 
of a serum sample of a patient receiving flecainide is shown in Fig. 1. A compar- 
ison of the results from twenty serum samples analysed either in the laboratories 
of Kettelhack Riker (by a HPLC method already published [ 91, with replace- 
ment of UV detection by fluorescence detection) and in our laboratory (by the 
present HPLC method) is shown in Fig. 2. In Table II the serum levels of one 
serum sample determined repeatedly during one year (storage at - 20” C) are 
shown. The UV spectrum of flecainide acetate is displayed in Fig. 3. 
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TABLE II 
STABILITY OF SERUM FLECAINIDE DURING STORAGE AT -20°C 
Duration of storage Serum flecainide level 
(weeks ) &g/ml ) 
0 0.80 
0.5 0.76 
1 0.85 
2 0.89 
4 0.81 
6 0.83 
11 0.85 
36 0.83 
52 0.84 
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Fig. 3. UV spectrum of flecainide acetate (the cross is at 222 nm). 
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Using the method of Boutagy et al. we had severe problems [“clotting” of both 
aqueous phases (2 M sodium hydroxide and 0.1 M phosphoric acid) after nearly 
complete removal of the diethyl ether phase in the large majority of samples]. 
The recovery rates (meant S.D.) for flecainide were 81.7 2 2.6% for modification 
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I, 82.6 + 16.6% for modification II, 73.1% 9.2% for modification III and 79.6 + 5.1% 
for modification IV (mean i S.D. of nine determinations each). 
DISCUSSION 
Direct fluorometric [ 10,111, gas chromatographic (GC) [ 121 or HPLC meth- 
ods with either fluorescence detection [ 13-171 or UV detection [9,16,18,19] have 
been used for the determination of serum or plasma levels of flecainide acetate. 
The main disadvantage of direct fluorometric methods [ 10,111 is a lack of spec- 
ificity due to interference from other drugs. GC methods [ 121 are specific and 
highly sensitive but rather time-consuming, and require equipment not routinely 
available in clinical laboratories. HPLC methods with fluorescence detection 
[ 13-171 show adequate sensitivity and specificity, although many laboratories 
do not possess a fluorescence detector. In addition, the method of De Jong et al. 
[ 131 lacks an internal standard, has only a relatively moderate recovery of ca. 
65% and requires an expensive and sophisticated spectrofluorometer and cutting 
a commercial column. The method of Chang et al. [ 161 also has a relatively mod- 
erate recovery of ca. 65-70%, whereas the recovery was not reported by Bhamra 
et al. [14] or Chang et al. [ 151. In contrast, Plomp et al. [ 171 demonstrated 
complete recovery, using a bonded-phase extraction column procedure identical 
with that of Chang et al. [ 161. HPLC methods with UV detection [9,16,18,19] 
are sensitive and specific means for determination of serum or plasma flecainide 
acetate levels, although the method of Chang et al. [ 181 has a relatively moderate 
recovery of ca. 67% and is rather time-consuming owing to a complicated liq- 
uid-liquid extraction procedure. Similar extraction recoveries (concentration 
range 3-25 ng/ml, 57-67%, concentration range 50-1600 ng/ml, 73-79% ) were 
reported by Chang et al. in another paper [ 161. Becker [ 91 reported a recovery 
of ca. 80% using a bonded-phase extraction column procedure. 
UV detection is performed at 298 or 308 nm in the above-mentioned studies 
[9,16,18], probably in order to minimize spectral interference, though the maxi- 
mum absorbance peak of flecainide acetate occurs at ca. 213 nm. Boutagy et al. 
[ 191 demonstrated detection at a wavelength as low as 214 nm with a recovery of 
89-95% for flecainide and of 86% for the internal standard. However, in our hands 
the extraction procedure of Boutagy et al. [ 191 revealed severe problems and after 
some necessary modifications the recovery was comparatively low. Because of 
those facts and of some minor disadvantages (diethyl ether extraction, varying 
quality of different PBondapak C,, reversed-phase columns, use of a precolumn) 
we consider our method to have marked advantages. Besides, no data about pa- 
tients’ plasma flecainide levels were given by Boutagy et al. [ 191. To allow detec- 
tion at a wavelength near the maximum absorbance the mobile phase has to be 
adapted as mentioned above. Using the chromatographic conditions described, 
flecainide acetate could be detected at 222 nm at a low detector range of 0.02 
a.u.f.s., thus improving the signal-to-noise ratio compared with detection at a 
higher wavelength. A recovery rate of 99.5% for flecainide acetate was obtained 
due to our extraction procedure. In addition the present extraction procedure is 
rapid and inexpensive (e.g. no use of a bonded-phase extraction column). No 
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cardiovascular substance or endogenous substance was observed as an interfering 
peak, although many substances absorb at 222 nm. The presently reported HPLC 
method for the assay of flecainide acetate serum levels is rapid, sensitive, specific, 
inexpensive and can be performed in every laboratory possessing an HPLC sys- 
tem with a variable-wavelength UV detector without need for additional equip- 
ment. Thus, this method is suitable for monitoring therapeutic and toxic serum 
levels of flecainide acetate. Serum samples can be stored at - 20” C for at least a 
year without deterioration of the drug. An excellent correlation with an estab- 
lished HPLC method is demonstrated, and mean trough serum levels of flecainide 
acetate are demonstreated to be 0.37 + 0.20 pg/ml (200 mg of flecainide orally per 
day) or 0.50 + 0.24 pug/ml (300 mg of flecainide orally per day) in patients on 
chronic flecainide therapy using the reported HPLC method. 
In conclusion, this newly developed HPLC method is suitable for the clinical 
management of patients, especially because of its simplicity, rapidity and accuracy. 
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